BASKING RIDGE, N.J., Feb. 23, 2011 /PRNewswire/ — Regado
Biosciences, a privately held company leading the development of
antithrombotic aptamers with active control agents, announced that
Ellen McDonald, MBA, Senior Vice President and Chief Business
Officer, will be speaking and participating on a panel that will
highlight new and innovative cardiovascular drug therapies at the
2011 RBC Capital Markets Healthcare Conference. The panel
discussion will be held at the New York Palace Hotel in New York
City on Wednesday, March 2, 2011 at 2:35 p.m. EST in Holmes 1.
ABOUT REGADO BIOSCIENCES
Regado Biosciences, Inc. is a private biopharmaceutical company
pioneering a new therapeutic technology with the creation and
development of proprietary controllable aptamer drug systems.
Each system comprises a nuclease-stabilized RNA aptamer, the
therapeutic effect of which can be reversed partially or completely
in real time by its specific and complementary oligonucleotide
active control agent. This technology is being applied to
injectable antithrombotics (including anticoagulants and
antiplatelet agents) in the acute and sub-acute care cardiovascular
setting, a multi-billion dollar world-wide market in need of drugs
with improved safety profiles and a greater degree of therapeutic
control. The products in Regado’s pipeline are designed to
act as optimized antithrombotics, uniquely concomitantly minimizing
the risk of ischemia and bleeding, and, by allowing patient
specific tuning of the desired therapeutic effect, providing a safe
and unique approach to personalized medicine.
ABOUT REG1, REG2 and REG3
Regado’s lead program, the anticoagulant system REG1, consists
of two parenteral agents both administered by IV bolus, the first
being a potent highly selective Factor IXa inhibitor (pegnivacogin,
a.k.a. RB006) and the second being its complementary active control
agent (anivamersen, a.k.a. RB007). Anivamersen c
‘/>”/>
